Neuravi receives US patents for neurovascular clot capture and retrieval


Neuravi has announced that the US Patent Office has approved two patents covering its therapeutic platform for the endovascular treatment of acute ischaemic stroke.

The granting of US Patent #8,852,205 “Clot Retrieval Device for Removing Occlusive Clot from a Blood Vessel” and US Patent #8,777,976 B2 “Clot Capture Systems and Associated Methods” expands Neuravi’s US granted portfolio to 33 patents. These new patents disclose unique design elements intended to enable both clot disengagement and capture and so facilitate the protected removal of hazardous clot from the brain. The CE-marked Embotrap revascularisation system incorporates these advanced features into its design.

According to David Vale, chief technology officer for Neuravi, the company has established its extensive portfolio by a combination of external licensing and internal R&D. “This approach has given us a great combination of very early priority filings on the base technology as well as strong protection on the more advanced third generation features. The extensive Neuravi patent portfolio continues to be strengthened by our R&D team’s commitment to developing technologies that tackle some of the most daunting clinical challenges in treating this patient population,” says Vale.

The Embotrap revascularisation device takes an inside-out approach to rapidly and safely restoring blood flow to the affected brain tissue. The device is designed to trap the clot inside a proprietary structure that the company calls a Stent-Trap while the device restores blood flow to the brain. The Stent-Trap structure is engineered to retain the clot during the retrieval process, and features a multi-dimensional fragment protection zone. Physicians have observed that minimizing distal and new territory embolisation during endovascular stroke therapy may play an important role in patient outcomes.

The EmboTrap received CE mark approval in 2013 and is not yet available for use in the United States.